<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_mouse" title="Genomic Perspective on Mouse Liver Cancer Models" shortTitle="mouse" author="Sun  Young Yim, Ju-Seog Lee" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2072-6694/11/11/1648/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
2.	LS	2.
</s>
<s type="frag">
Conventional	JJ	Conventional
Mouse	NNP	Mouse
Models	NNS	model
for	IN	for
Liver	NNP	Liver
Cancer	NN	cancer
</s>
</head>
<p>
<s type="decl">
A	DT	a
relatively	RB	relatively
large	JJ	large
number	NN	number
of	IN	of
mouse	NN	mouse
models	NNS	model
are	VBP	be
presently	RB	presently
available	JJ	available
for	IN	for
the	DT	the
study	NN	study
of	IN	of
hepatocarcinogenesis	NN	hepatocarcinogenesis
.	.	.
</s>
<s type="decl">
The	DT	the
common	JJ	common
ones	NNS	one
are	VBP	be
chemically	RB	chemically
induced	VBN	induce
models	NNS	model
,	,	,
genetically	RB	genetically
engineered	VBN	engineer
mouse	NN	mouse
(	-LRB-	(
GEM	NNP	GEM
)	-RRB-	)
models	NNS	model
,	,	,
implantation	NN	implantation
models	NNS	model
,	,	,
and	CC	and
viral	JJ	viral
models	NNS	model
.	.	.
</s>
<s type="decl">
Our	PRP$	our
aim	NN	aim
here	RB	here
is	VBZ	be
not	RB	not
to	TO	to
review	VB	review
all	DT	all
mouse	NN	mouse
models	NNS	model
for	IN	for
liver	NN	liver
cancer	NN	cancer
but	CC	but
rather	RB	rather
to	TO	to
provide	VB	provide
examples	NNS	example
of	IN	of
the	DT	the
representative	JJ	representative
ones	NNS	one
,	,	,
mostly	RB	mostly
chemically	RB	chemically
induced	VBN	induce
or	CC	or
genetically	RB	genetically
engineered	VBN	engineer
models	NNS	model
(	-LRB-	(
GEMs	NNS	GEM
)	-RRB-	)
that	WDT	that
have	VBP	have
been	VBN	be
integrated	VBN	integrate
to	IN	to
genomics	NN	genomic
of	IN	of
human	JJ	human
HCCs	NNS	HCC
(	:	(
</s>
<figure>
<s type="frag">
Figure	NNP	Figure
1	CD	1
</s>
</figure>
<s type="frag">
)	-RRB-	)
.	.	.
</s>
</p>
<head>
<s type="frag">
2.1.	CD	2.1.
Chemically	RB	chemically
Induced	VBN	induce
Models	NNS	model
</s>
</head>
<p>
<s type="decl">
Chemically	RB	chemically
induced	VBN	induce
hepatocarcinogenesis	NN	hepatocarcinogenesis
is	VBZ	be
caused	VBN	cause
by	IN	by
an	DT	a
irreversible	JJ	irreversible
process	NN	process
of	IN	of
structural	JJ	structural
DNA	NNP	NN
changes	NNS	change
.	.	.
</s>
<s type="decl">
The	DT	the
most	RBS	most
widely	RB	widely
used	VBN	use
chemical	NN	chemical
to	TO	to
induce	VB	induce
liver	NN	liver
cancer	NN	cancer
in	IN	in
mice	NNS	mouse
is	VBZ	be
diethylnitrosamine	NN	diethylnitrosamine
(	-LRB-	(
DEN	NNP	DEN
)	-RRB-	)
(	-LRB-	(
Table	NNP	Table
1	CD	1
)	-RRB-	)
.	.	.
</s>
<s type="decl">
DEN	NNP	DEN
is	VBZ	be
a	DT	a
DNA	NN	DNA
alkylating	NN	alkylating
agent	NN	agent
and	CC	and
when	WRB	when
injected	VBN	inject
into	IN	into
juvenile	JJ	juvenile
mice	NNS	mouse
,	,	,
it	PRP	it
forms	VBZ	form
mutagenic	JJ	mutagenic
DNA	NN	DNA
adducts	NNS	adduct
,	,	,
which	WDT	which
are	VBP	be
generated	VBN	generate
rapidly	RB	rapidly
in	IN	in
centrilobular	JJ	centrilobular
hepatocytes	NNS	hepatocyte
.	.	.
</s>
<s type="decl">
DEN	NNP	DEN
is	VBZ	be
metabolic	NN	metabolic
activated	VBN	activate
in	IN	in
hepatocytes	NNS	hepatocyte
by	IN	by
enzymes	NNS	enzyme
of	IN	of
the	DT	the
cytochrome	NN	cytochrome
P450	NNP	P450
family	NN	family
and	CC	and
acts	VBZ	act
as	IN	as
a	DT	a
complete	JJ	complete
carcinogen	NN	carcinogen
if	IN	if
injected	VBN	inject
into	IN	into
young	JJ	young
mice	NNS	mouse
younger	JJR	young
than	IN	than
two	CD	2
weeks	NNS	week
old	JJ	old
with	IN	with
actively	RB	actively
proliferating	VBG	proliferate
hepatocytes	NNS	hepatocyte
resulting	VBG	result
in	IN	in
dysplastic	JJ	dysplastic
nodules	NNS	nodule
,	,	,
which	WDT	which
progress	VBP	progress
to	IN	to
carcinoma	NN	carcinoma
.	.	.
</s>
<s type="decl">
If	IN	if
given	VBN	give
to	IN	to
an	DT	a
older	JJR	old
mouse	NN	mouse
,	,	,
additional	JJ	additional
stimulation	NN	stimulation
is	VBZ	be
required	VBN	require
for	IN	for
instance	NN	instance
,	,	,
phenobarbital	NN	phenobarbital
(	-LRB-	(
PB	NN	PB
)	-RRB-	)
,	,	,
carbon	NN	carbon
tetrachloride	NN	tetrachloride
,	,	,
or	CC	or
high-fat	JJ	high-fat
diet	NN	diet
feeding	NN	feeding
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
oxidative	JJ	oxidative
stress	NN	stress
induced	VBN	induce
by	IN	by
reactive	JJ	reactive
oxygen	NN	oxygen
species	NNS	species
(	-LRB-	(
ROS	NNS	ROS
)	-RRB-	)
during	IN	during
DEN	NNP	DEN
metabolization	NN	metabolization
is	VBZ	be
known	VBN	know
to	TO	to
contribute	VB	contribute
to	IN	to
hepatocarcinogenesis	NN	hepatocarcinogenesis
as	IN	as
they	PRP	they
cause	VBP	cause
DNA	NN	DNA
,	,	,
protein	NN	protein
,	,	,
and	CC	and
lipid	NN	lipid
damage	NN	damage
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
mutational	JJ	mutational
landscape	NN	landscape
of	IN	of
a	DT	a
DEN-induced	JJ	DEN-induced
tumor	NN	tumor
was	VBD	be
described	VBN	describe
in	IN	in
a	DT	a
recent	JJ	recent
study	NN	study
using	VBG	use
the	DT	the
whole	JJ	whole
exome	NN	exome
sequencing	NN	sequencing
technique	NN	technique
.	.	.
</s>
<s type="decl">
A	DT	a
high	JJ	high
burden	NN	burden
of	IN	of
somatic	JJ	somatic
mutation	NN	mutation
was	VBD	be
observed	VBN	observe
and	CC	and
almost	RB	almost
all	DT	all
of	IN	of
the	DT	the
DNA	NN	DNA
changes	NNS	change
in	IN	in
the	DT	the
DEN-induced	JJ	DEN-induced
tumors	NNS	tumor
were	VBD	be
single-base	JJ	single-base
substitutions	NNS	substitution
.	.	.
</s>
<s type="decl">
Four	CD	4
recurrently	RB	recurrently
mutated	VBN	mutate
genes	NNS	gene
that	WDT	that
are	VBP	be
putative	JJ	putative
oncogenic	JJ	oncogenic
drivers	NNS	driver
of	IN	of
DEN-induced	NN	den-induced
tumors	NNS	tumor
were	VBD	be
<hi rend="italic">
Hras	NNP	Hras
</hi>
,	,	,
<hi rend="italic">
Braf	NNP	Braf
</hi>
,	,	,
<hi rend="italic">
Egfr	NNP	Egfr
</hi>
,	,	,
and	CC	and
<hi rend="italic">
Apc	NNP	Apc
</hi>
.	.	.
</s>
<s type="decl">
The	DT	the
incidence	NN	incidence
of	IN	of
<hi rend="italic">
Hras	NNP	Hras
</hi>
was	VBD	be
the	DT	the
highest	JJS	high
reaching	VBG	reach
approximately	RB	approximately
80	CD	80
%	NN	%
suggesting	VBG	suggest
selective	JJ	selective
advantage	NN	advantage
during	IN	during
hepatocarcinogenesis	NN	hepatocarcinogenesis
.	.	.
</s>
<s type="decl">
<hi rend="italic">
Hras	NNPS	Hras
</hi>
,	,	,
<hi rend="italic">
Braf	NNP	Braf
</hi>
,	,	,
and	CC	and
<hi rend="italic">
Egfr	NNP	Egfr
</hi>
mutations	NNS	mutation
were	VBD	be
present	JJ	present
in	IN	in
every	DT	every
DEN-induced	NNP	DEN-induced
HCC	NNP	HCC
with	IN	with
mutual	JJ	mutual
exclusivity	NN	exclusivity
and	CC	and
may	MD	may
replace	VB	replace
each	DT	each
other	JJ	other
in	IN	in
terms	NNS	term
of	IN	of
oncogenic	JJ	oncogenic
drivers	NNS	driver
.	.	.
</s>
<s type="decl">
Activation	NN	Activation
of	IN	of
the	DT	the
<hi rend="italic">
Ras/Raf/MEK/ERK	NNP	Ras/Raf/MEK/ERK
</hi>
signal	NN	signal
transduction	NN	transduction
pathway	NN	pathway
was	VBD	be
the	DT	the
hallmark	JJ	hallmark
feature	NN	feature
in	IN	in
the	DT	the
DEN-induced	NN	den-induced
mouse	NN	mouse
model	NN	model
which	WDT	which
is	VBZ	be
rare	JJ	rare
in	IN	in
human	JJ	human
HCC	NNP	HCC
.	.	.
</s>
<s type="decl">
Of	IN	of
note	NN	note
,	,	,
<hi rend="italic">
TP53	NNP	TP53
</hi>
and	CC	and
<hi rend="italic">
CTNNB1	NNP	CTNNB1
</hi>
,	,	,
the	DT	the
most	RBS	most
frequently	RB	frequently
altered	VBN	alter
genes	NNS	gene
in	IN	in
human	NN	human
were	VBD	be
never	RB	never
found	VBN	find
in	IN	in
DEN-induced	NN	den-induced
tumors	NNS	tumor
.	.	.
</s>
<s type="decl">
Although	IN	although
<hi rend="italic">
ctnnb1	NN	ctnnb1
</hi>
mutation	NN	mutation
is	VBZ	be
not	RB	not
observed	VBN	observe
in	IN	in
DEN-induced	JJ	DEN-induced
model	NN	model
,	,	,
its	PRP$	its
mutation	NN	mutation
is	VBZ	be
known	VBN	know
to	TO	to
be	VB	be
observed	VBN	observe
in	IN	in
a	DT	a
two-stage	JJ	two-stage
model	NN	model
,	,	,
the	DT	the
DEN-initiated	VBN	DEN-initiate
and	CC	and
PB-promoted	VBN	pB-promote
protocol	NN	protocol
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
loss	NN	loss
of	IN	of
<hi rend="italic">
Apc	NN	Apc
</hi>
function	NN	function
,	,	,
mutation	NN	mutation
and	CC	and
aberrant	JJ	aberrant
nuclear	JJ	nuclear
expression	NN	expression
of	IN	of
β-catenin	NN	β-catenin
may	MD	may
disrupt	VB	disrupt
the	DT	the
canonical	JJ	canonical
Wnt/β-catenin	NN	Wnt/β-catenin
pathway	NN	pathway
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
Stelic	NNP	Stelic
Animal	NNP	Animal
Model	NNP	Model
(	-LRB-	(
STAM	NNP	STAM
)	-RRB-	)
demonstrates	VBZ	demonstrate
non-alcoholic	JJ	non-alcoholic
steatohepatitis	NN	steatohepatitis
(	-LRB-	(
NASH	NNP	NASH
)	-RRB-	)
progression	NN	progression
resembling	VBG	resemble
the	DT	the
disease	NN	disease
in	IN	in
humans	NNS	human
.	.	.
</s>
<s type="decl">
Since	IN	since
NASH	NNP	NASH
is	VBZ	be
evolving	VBG	evolve
as	IN	as
a	DT	a
major	JJ	major
cause	NN	cause
of	IN	of
non-viral	JJ	non-viral
HCC	NN	HCC
and	CC	and
may	MD	may
account	VB	account
for	IN	for
a	DT	a
large	JJ	large
proportion	NN	proportion
of	IN	of
HCC	NNP	HCC
in	IN	in
developed	JJ	developed
countries	NNS	country
in	IN	in
recent	JJ	recent
years	NNS	year
,	,	,
HCC	NNP	HCC
arising	VBG	arise
from	IN	from
NASH	NNP	NASH
is	VBZ	be
important	JJ	important
.	.	.
</s>
<s type="decl">
The	DT	the
STAM	NNP	STAM
model	NN	model
is	VBZ	be
created	VBN	create
by	IN	by
combination	NN	combination
of	IN	of
chemical	NN	chemical
(	-LRB-	(
a	DT	a
single	JJ	single
subcutaneous	JJ	subcutaneous
injection	NN	injection
of	IN	of
200	CD	200
μg	NN	μg
of	IN	of
streptozotocin	NN	streptozotocin
at	IN	at
two	CD	2
days	NNS	day
after	IN	after
birth	NN	birth
)	-RRB-	)
and	CC	and
dietary	JJ	dietary
intervention	NN	intervention
(	-LRB-	(
high-fat	JJ	high-fat
diet	NN	diet
ad	NN	ad
libitum	NN	libitum
four	CD	4
weeks	NNS	week
after	IN	after
injection	NN	injection
)	-RRB-	)
in	IN	in
C57BL/6	NNP	C57BL/6
mice	NNS	mouse
.	.	.
</s>
<s type="decl">
STAM	NNP	STAM
mice	NNS	mouse
manifest	VBP	manifest
NASH	NNP	NASH
at	IN	at
eight	CD	8
weeks	NNS	week
,	,	,
which	WDT	which
progresses	VBZ	progress
to	IN	to
fibrosis	NN	fibrosis
at	IN	at
12	CD	12
weeks	NNS	week
,	,	,
and	CC	and
eventually	RB	eventually
develops	VBZ	develop
into	IN	into
HCC	NNP	HCC
at	IN	at
a	DT	a
rate	NN	rate
of	IN	of
nearly	RB	nearly
100	CD	100
%	NN	%
in	IN	in
males	NNS	male
.	.	.
</s>
<s type="decl">
The	DT	the
STAM	NNP	STAM
model	NN	model
had	VBD	have
pathway	NN	pathway
mutation	NN	mutation
rates	NNS	rate
comparable	JJ	comparable
to	IN	to
those	DT	this
in	IN	in
humans	NNS	human
for	IN	for
most	JJS	most
pathways	NNS	pathway
with	IN	with
more	JJR	more
alterations	NNS	alteration
in	IN	in
receptor	NN	receptor
tyrosine	NN	tyrosine
kinase	NN	kinase
(	-LRB-	(
RTK	NN	RTK
)	-RRB-	)
signaling	NN	signaling
and	CC	and
chromatin-modification	JJ	chromatin-modification
genes	NNS	gene
.	.	.
</s>
<s type="decl">
This	DT	this
model	NN	model
also	RB	also
showed	VBD	show
low	JJ	low
mutation	NN	mutation
rate	NN	rate
of	IN	of
<hi rend="italic">
TP53	NNP	TP53
</hi>
but	CC	but
the	DT	the
cell-cycle	NN	cell-cycle
pathway	NN	pathway
alteration	NN	alteration
rate	NN	rate
was	VBD	be
similar	JJ	similar
to	IN	to
human	JJ	human
tumors	NNS	tumor
.	.	.
</s>
<s type="decl">
The	DT	the
limitation	NN	limitation
of	IN	of
this	DT	this
model	NN	model
is	VBZ	be
that	IN	that
the	DT	the
model	NN	model
does	VBZ	do
not	RB	not
show	VB	show
obesity	NN	obesity
or	CC	or
insulin	NN	insulin
resistance	NN	resistance
,	,	,
which	WDT	which
is	VBZ	be
the	DT	the
common	JJ	common
characteristics	NNS	characteristic
of	IN	of
patients	NNS	patient
with	IN	with
NASH	NNP	NASH
.	.	.
</s>
</p>
<head>
<s type="frag">
2.2.	CD	2.2.
Genetically	RB	genetically
Engineered	VBN	Engineer
Mouse	NNP	Mouse
Models	NNS	model
</s>
</head>
<p>
<s type="decl">
Genetically	RB	genetically
engineered	VBN	engineer
mouse	NN	mouse
(	-LRB-	(
GEM	NNP	GEM
)	-RRB-	)
models	NNS	model
recapitulate	VBP	recapitulate
the	DT	the
multistep	NN	multistep
process	NN	process
of	IN	of
hepatocarcinogenesis	NN	hepatocarcinogenesis
with	IN	with
multiple	JJ	multiple
genetic	JJ	genetic
and	CC	and
epigenetic	JJ	epigenetic
changes	NNS	change
occurring	VBG	occur
along	IN	along
each	DT	each
stage	NN	stage
of	IN	of
progression	NN	progression
toward	IN	toward
cancer	NN	cancer
formation	NN	formation
.	.	.
</s>
<s type="decl">
They	PRP	they
are	VBP	be
highly	RB	highly
useful	JJ	useful
for	IN	for
assessing	VBG	assess
the	DT	the
impacts	NNS	impact
of	IN	of
a	DT	a
driver	NN	driver
oncogene	NN	oncogene
alone	RB	alone
or	CC	or
in	IN	in
combination	NN	combination
with	IN	with
other	JJ	other
driver	NN	driver
oncogenes	NNS	oncogen
or	CC	or
tumor	NN	tumor
suppressors	NNS	suppressor
.	.	.
</s>
<s type="decl">
Recently	RB	recently
,	,	,
the	DT	the
Cancer	NNP	Cancer
Genome	NNP	Genome
Atlas	NNP	Atlas
(	-LRB-	(
TCGA	NNP	TCGA
)	-RRB-	)
characterized	VBD	characterize
the	DT	the
genomic	JJ	genomic
landscape	NN	landscape
of	IN	of
HCC	NNP	HCC
using	VBG	use
large-scale	JJ	large-scale
multi-platform	JJ	multi-platform
analysis	NN	analysis
of	IN	of
HCC	NNP	HCC
,	,	,
including	VBG	include
evaluation	NN	evaluation
of	IN	of
somatic	JJ	somatic
mutations	NNS	mutation
and	CC	and
copy	NN	copy
number	NN	number
alterations	NNS	alteration
.	.	.
</s>
<s type="decl">
Commonly	RB	commonly
altered	VBN	alter
pathways	NNS	pathway
such	JJ	such
as	IN	as
cell	NN	cell
cycle	NN	cycle
pathway	NN	pathway
,	,	,
RTK/RAS/PI3K	NNP	RTK/RAS/PI3K
,	,	,
and	CC	and
WNT	NNP	WNT
pathways	NNS	pathway
were	VBD	be
also	RB	also
identified	VBN	identify
and	CC	and
therefore	RB	therefore
,	,	,
data	NNS	datum
generated	VBN	generate
from	IN	from
GEMs	NNPS	GeM
would	MD	would
be	VB	be
useful	JJ	useful
in	IN	in
developing	VBG	develop
novel	JJ	novel
therapies	NNS	therapy
and	CC	and
be	VB	be
tested	VBN	test
in	IN	in
the	DT	the
preclinical	JJ	preclinical
setting	NN	setting
if	IN	if
they	PRP	they
recapitulate	VBP	recapitulate
human	JJ	human
HCCs	NNP	HCC
.	.	.
</s>
</p>
</text>